SCHEMBL17287802

SCHEMBL17287802

O=C(Nc1cccc(Cl)c1)Nc1nc2ccc(C(F)(F)F)cc2s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK1D P48730 9/20 0.68
▸ KDM4E B2RXH2 1/20 0.66
▸ MEN1 O00255 1/20 0.66
▸ ALDH1A1 P00352 1/20 0.66
▸ LMNA P02545 1/20 0.66
▸ POLB P06746 1/20 0.66
▸ MAPT P10636 1/20 0.66
▸ HTT P42858 1/20 0.66
▸ KMT2A Q03164 1/20 0.66
▸ ATM Q13315 1/20 0.66
▸ DYRK1A Q13627 3/20 0.61
▸ DYRK1B Q9Y463 2/20 0.58
▸ ACP1 P24666 1/20 0.58
▸ KDR P35968 1/20 0.56
▸ CXCR2 P25025 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ HSD17B10 Q99714 2/20 0.52
▸ CSNK2A2 P19784 1/20 0.52
▸ CSNK2B P67870 1/20 0.52
▸ CSNK2A1 P68400 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18375319 0.88 CSNK1D (0.74) CSNK1DMEN1LMNAPOLBMAPT
SCHEMBL23256548 0.84 CSNK1D (0.61) CSNK1DMEN1ALDH1A1MAPTKMT2A
SCHEMBL27093078 0.83 KDR (0.75) CSNK1DKDM4EMEN1ALDH1A1LMNA
SCHEMBL27093081 0.83 LMNA (0.70) KDM4EMEN1ALDH1A1LMNAPOLB
SCHEMBL21568039 0.83 LMNA (0.70) KDM4EMEN1ALDH1A1LMNAPOLB
SCHEMBL27093269 0.83 HSD17B10 (0.71) KDM4EMEN1ALDH1A1LMNAPOLB
SCHEMBL31206306 0.83 MAPT (0.73) CSNK1DKDM4EMEN1ALDH1A1LMNA
SCHEMBL6225459 0.83 MAPT (0.73) CSNK1DKDM4EMEN1ALDH1A1LMNA
SCHEMBL21568075 0.83 CSNK1D (0.59) CSNK1DKDM4EMEN1ALDH1A1LMNA
SCHEMBL27093085 0.82 HSD17B10 (0.72) KDM4EMEN1ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3348550-B1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR INVESTIGACION (ES) 2019-04-24 — — EP claimed
EP-3348550-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2018-07-18 — — EP claimed
US-9592224-B2 Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2017-03-14 — — US claimed
US-20150352082-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2015-12-10 — — US claimed
EP-2949651-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior De Investigaciones Científicas (CSIC) (ES) 2015-12-02 — — EP claimed
EP-3348550-B1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR INVESTIGACION (ES) 2019-04-24 — — EP disclosed
EP-3348550-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2018-07-18 — — EP disclosed
US-9592224-B2 Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2017-03-14 — — US disclosed
US-20150352082-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2015-12-10 — — US disclosed
EP-2949651-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES Consejo Superior De Investigaciones Científicas (CSIC) (ES) 2015-12-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150352082-A1 SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES CSNK1A1, CRY1, CSNK1G1 CSNK1D 13/4885KDM4E 360/4885MEN1 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback